Following some uncertainty due to Brexit, the government has committed to ensuring that the UK is as aligned as possible with the new EU Clinical Trials Regulation (CTR) when it comes into force.
The commitment was made following a debate on a proposed Bill amendment which was supported by a range of science and research organisations including AMRC (the Association of Medical Research Charities), who provided us with this information.
Alignment of the clinical trials landscape across the EU is vital to allow patients to take part in pioneering pan-EU trials. Ensuring full alignment with the CTR is one of AMRC’s key priorities for patients and medical research post-Brexit.
Ataxia UK is a member of the AMRC. You can read their position statement on exiting the European Union here.
Posted on 23/05/2018
